1. Stavros V. Konstantinides et al. JACC 2016;67:976-990
PE: Risk-Adjusted Management in the Acute Phase and Over the Long Term *Biochemical markers include markers of myocardial injury (troponins, heart-type fatty acid-binding protein) and markers of heart failure (BNP or N-terminal-proBNP). †Only antiphospholipid syndrome and high-risk inherited thrombophilia (i.e., homozygosity for factor V Leiden, homozygosity for prothrombin G20210A mutation, double heterozygosity, antithrombin deficiency) are considered. Nevertheless, routine thrombophilia testing is not indicated in PE patients. BNP = B-type natriuretic peptide; CT = computed tomography; CTEPH = chronic thromboembolic pulmonary hypertension; CTPA = computed tomographic pulmonary angiogram; CUS = compression ultrasound; Echo = echocardiography; N-terminal-proBNP = N-terminal pro–B-type natriuretic peptide; PE = pulmonary embolism; PESI = pulmonary embolism severity index; RV = right ventricular; sPESI = simplified pulmonary embolism severity index; V/Q scan = ventilation/perfusion lung scan; VTE = venous thromboembolism.
Stavros V. Konstantinides et al. JACC 2016;67:
American College of Cardiology Foundation